Agreement between Swiss Acino and UAE-based EU GMP-licensed Pharmax covers the licensing, manufacturing, and supply of select Acino products across the Middle East and Africa, based on the local needs of patients.
Eugene Zaika explains how the company’s sustainable development strategy fits into its business.
Zurich, Switzerland and Moscow, Russia, 1 April 2021
Acino will supply medicines for children with mental and behavioral disorders, schizophrenia, affective disorders, and hyperkinetic disorders
This World Heart Day, September 29, and for the next year, Acino will support the World Heart Federation to raise awareness of cardiovascular disease (CVD) as the leading cause of death for patients around the world
Acino and Takeda Pharmaceuticals announced today the completion of the acquisition for parts of Takeda’s primary care portfolio in selected countries in the Middle East, Africa, and Ukraine.